Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in R
false
קמהדע בע"מ
2
380
KAMADA LTD
Corporation no:
511524605
16035
Israel Securities Authority
Tel Aviv Stock Exchange
C002
(
Public
)
Reported via MAGNA:
08/12/2025
www.isa.gov.il
www.tase.co.il
Reference:
2025-02-097714
Time of broadcast:
13:16
13:16
The corporation scheduled the publication of the report to
08/12/2025 14:00
Immediate Report
Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on
Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full- Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026 הנהלת החברה תקיים וובינר בעברית (בנוסף על הוובינר באנגלית) בשעה 16:00 בקישור https://us02web.zoom.us/webinar/register/WN_FJS1wG_bSUyDPzMQX2wy1A
1765191902_ea026878601_6k_kamadaEDGAR3_Bannerless_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market:
TASE
Date of revision of form structure:
06/08/2024
Address:
Holtzman 2
4081
,
Rehovot
7670402
ISRAEL
,
Tel:
08-9406472
,
Fax:
08-9406473
E-mail address:
Mosheb@kamada.com
Company site:
www.kamada.com
Previous names of reporting entity:
Name of the Signatory:
מירל אבירן
Position of Signatory in the reporting corporation:
Name of Employer Company:
Address:
ד.נ נגב
,
בית קמה
8532500
Telephone:
054-5392955
Facsimile:
08-9406473
E-mail:
aviranm@kamada.com
2